Helfrich W - Search Results

1

A CSPG4-specific immunotoxin kills rhabdomyosarcoma cells and binds to primary tumor tissues.

Brehm H, Niesen J, Mladenov R, Stein C, Pardo A, Fey G, Helfrich W, Fischer R, Gattenlöhner S, Barth S. Brehm H, et al. Among authors: helfrich w. Cancer Lett. 2014 Oct 1;352(2):228-35. doi: 10.1016/j.canlet.2014.07.006. Epub 2014 Jul 10. Cancer Lett. 2014. PMID: 25016058

2

Target cell-restricted apoptosis induction of acute leukemic T cells by a recombinant tumor necrosis factor-related apoptosis-inducing ligand fusion protein with specificity for human CD7.

Bremer E, Samplonius DF, Peipp M, van Genne L, Kroesen BJ, Fey GH, Gramatzki M, de Leij LF, Helfrich W. Bremer E, et al. Among authors: helfrich w. Cancer Res. 2005 Apr 15;65(8):3380-8. doi: 10.1158/0008-5472.CAN-04-2756. Cancer Res. 2005. PMID: 15833872

3

Selective induction of apoptosis in leukemic B-lymphoid cells by a CD19-specific TRAIL fusion protein.

Stieglmaier J, Bremer E, Kellner C, Liebig TM, ten Cate B, Peipp M, Schulze-Koops H, Pfeiffer M, Bühring HJ, Greil J, Oduncu F, Emmerich B, Fey GH, Helfrich W. Stieglmaier J, et al. Among authors: helfrich w. Cancer Immunol Immunother. 2008 Feb;57(2):233-46. doi: 10.1007/s00262-007-0370-8. Epub 2007 Jul 31. Cancer Immunol Immunother. 2008. PMID: 17665197 Free PMC article.

4

Superior activity of fusion protein scFvRit:sFasL over cotreatment with rituximab and Fas agonists.

Bremer E, ten Cate B, Samplonius DF, Mueller N, Wajant H, Stel AJ, Chamuleau M, van de Loosdrecht AA, Stieglmaier J, Fey GH, Helfrich W. Bremer E, et al. Among authors: helfrich w. Cancer Res. 2008 Jan 15;68(2):597-604. doi: 10.1158/0008-5472.CAN-07-5171. Cancer Res. 2008. PMID: 18199557

5

A novel AML-selective TRAIL fusion protein that is superior to Gemtuzumab Ozogamicin in terms of in vitro selectivity, activity and stability.

ten Cate B, Bremer E, de Bruyn M, Bijma T, Samplonius D, Schwemmlein M, Huls G, Fey G, Helfrich W. ten Cate B, et al. Among authors: helfrich w. Leukemia. 2009 Aug;23(8):1389-97. doi: 10.1038/leu.2009.34. Epub 2009 Mar 5. Leukemia. 2009. PMID: 19262596

6

Melanoma-associated Chondroitin Sulfate Proteoglycan (MCSP)-targeted delivery of soluble TRAIL potently inhibits melanoma outgrowth in vitro and in vivo.

de Bruyn M, Rybczynska AA, Wei Y, Schwenkert M, Fey GH, Dierckx RA, van Waarde A, Helfrich W, Bremer E. de Bruyn M, et al. Among authors: helfrich w. Mol Cancer. 2010 Nov 23;9:301. doi: 10.1186/1476-4598-9-301. Mol Cancer. 2010. PMID: 21092273 Free PMC article.

7

Antibody-based fusion proteins to target death receptors in cancer.

de Bruyn M, Bremer E, Helfrich W. de Bruyn M, et al. Among authors: helfrich w. Cancer Lett. 2013 May 28;332(2):175-83. doi: 10.1016/j.canlet.2010.11.006. Epub 2011 Jan 6. Cancer Lett. 2013. PMID: 21215513 Review.

8

SNAP-tag based agents for preclinical in vitro imaging in malignant diseases.

Amoury M, Blume T, Brehm H, Niesen J, Tenhaef N, Barth S, Gattenlöhner S, Helfrich W, Fitting J, Nachreiner T, Pardo A. Amoury M, et al. Among authors: helfrich w. Curr Pharm Des. 2013;19(30):5429-36. doi: 10.2174/13816128113199990405. Curr Pharm Des. 2013. PMID: 23431985

9

EpCAM-selective elimination of carcinoma cells by a novel MAP-based cytolytic fusion protein.

Hristodorov D, Amoury M, Mladenov R, Niesen J, Arens K, Berges N, Hein L, Di Fiore S, Pham AT, Huhn M, Helfrich W, Fischer R, Thepen T, Barth S. Hristodorov D, et al. Among authors: helfrich w. Mol Cancer Ther. 2014 Sep;13(9):2194-202. doi: 10.1158/1535-7163.MCT-13-0781. Epub 2014 Jun 30. Mol Cancer Ther. 2014. PMID: 24980949

10

Granzyme B-based cytolytic fusion protein targeting EpCAM specifically kills triple negative breast cancer cells in vitro and inhibits tumor growth in a subcutaneous mouse tumor model.

Amoury M, Kolberg K, Pham AT, Hristodorov D, Mladenov R, Di Fiore S, Helfrich W, Kiessling F, Fischer R, Pardo A, Thepen T, Hussain AF, Nachreiner T, Barth S. Amoury M, et al. Among authors: helfrich w. Cancer Lett. 2016 Mar 28;372(2):201-9. doi: 10.1016/j.canlet.2016.01.027. Epub 2016 Jan 21. Cancer Lett. 2016. PMID: 26806809

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

143 results

Search Page